Menu
1 min read · estimated
APPROVED USE
What FDA approved
First-line treatment for adults with metastatic non-small cell lung cancer, high PD-L1 expression by an FDA-approved test (at least 50% of tumor cells or immune-cell staining over at least 10% of tumor area), and no EGFR or ALK aberrations.
LAMPGEN ANALYSIS
Why it matters
Made single-agent immunotherapy available first line for an assay-defined high PD-L1 population.
What research teams should watch
Store the assay and scoring method and document EGFR and ALK results before treatment selection.
PRIMARY RECORDS